No change
Create an alert
Stocks and Shares ISADenali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Company Information
About this company
Key people
Julian C. Baker
Independent Chairman of the Board
Ryan J. Watts
President, Chief Executive Officer, Director
Alexander O. Schuth
Co-Founder, Chief Operating Officer, Head of Corporate Development
Peter Chin
Acting Chief Medical Officer, Head - Development
Steven E. Krognes
Director
Tim van Hauwermeiren
Director
Jennifer E. Cook
Independent Director
Jay T. Flatley
Director
Click to see more
Key facts
- Shares in issue158.68m
- EPICDNLI
- ISINUS24823R1059
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.18bn
- Employees503
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.